Company: BDRX
Filing Date: 2025-08-06
Form Type: 424B3
Source: 0001214659-25-011542
Chunk: 1

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-08-06
Form: 424B3
Chunk 1
---
 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-37652

Biodexa Pharmaceuticals PLC
(Translation of
registrant's name into English)

1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom
(Address of principal
executive office)</div>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
[ X ] Form 40-F [ ]

The information included in this report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-214969) and Form F-3 (File No. 333-233901) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

| Date: July 31, 2025 |     | Biodexa Pharmaceuticals PLC                      
 (Registrant)                                     
 /s/ Stephen Stamp                                |
|:--------------------|:----|:-------------------------------------------------|
|                     |     | Stephen Stamp                                    |
|                     |     | Chief Executive Officer, Chief Financial Officer |

EXHIBIT 99.1

<div align='center'>ADR Ratio Change Effective</div>

July 31, 2025

Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)

ADR Ratio Change Effective

ADSs Outstanding Post Ratio Change

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces the previously announced ratio change of its American Depositary Receipts (“ADR”) from one (1) ADR representing ten thousand (10,000) ordinary shares, to the new ratio of one (1) ADR representing one hundred thousand (100,000